Benjamin Xiaoyi Li

426 total citations
11 papers, 301 citations indexed

About

Benjamin Xiaoyi Li is a scholar working on Hematology, Oncology and Surgery. According to data from OpenAlex, Benjamin Xiaoyi Li has authored 11 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Oncology and 3 papers in Surgery. Recurrent topics in Benjamin Xiaoyi Li's work include Blood Coagulation and Thrombosis Mechanisms (4 papers), Venomous Animal Envenomation and Studies (3 papers) and Platelet Disorders and Treatments (3 papers). Benjamin Xiaoyi Li is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (4 papers), Venomous Animal Envenomation and Studies (3 papers) and Platelet Disorders and Treatments (3 papers). Benjamin Xiaoyi Li collaborates with scholars based in China, Canada and United States. Benjamin Xiaoyi Li's co-authors include Xiangrong Dai, Heyu Ni, Xi Lei, Tyler W. Stratton, Xiaohong Xu, Naadiya Carrim, Miguel A. D. Neves, Jianhua Xu, Thomas McKeown and Pingguo Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Benjamin Xiaoyi Li

11 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Xiaoyi Li China 6 132 81 67 50 45 11 301
Louise J. Eltringham‐Smith Canada 11 148 1.1× 110 1.4× 132 2.0× 71 1.4× 28 0.6× 28 443
Kathrin Schwierczek Germany 4 134 1.0× 44 0.5× 63 0.9× 45 0.9× 91 2.0× 5 345
Daniëlle M. Coenen Netherlands 6 69 0.5× 48 0.6× 58 0.9× 31 0.6× 50 1.1× 13 227
Jens Posma Netherlands 6 129 1.0× 86 1.1× 68 1.0× 67 1.3× 35 0.8× 15 299
Surasak Wichaiyo Thailand 11 138 1.0× 43 0.5× 90 1.3× 34 0.7× 86 1.9× 22 387
Péter Batár Hungary 9 238 1.8× 80 1.0× 86 1.3× 25 0.5× 38 0.8× 31 418
Iván Parra‐Izquierdo United States 11 77 0.6× 141 1.7× 90 1.3× 18 0.4× 65 1.4× 18 335
Wen Gao China 11 67 0.5× 98 1.2× 83 1.2× 14 0.3× 63 1.4× 21 344
Sascha Meyer dos Santos Germany 11 63 0.5× 54 0.7× 94 1.4× 28 0.6× 82 1.8× 16 352
Kristin N. Kornerup United Kingdom 6 136 1.0× 46 0.6× 134 2.0× 16 0.3× 163 3.6× 6 437

Countries citing papers authored by Benjamin Xiaoyi Li

Since Specialization
Citations

This map shows the geographic impact of Benjamin Xiaoyi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Xiaoyi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Xiaoyi Li more than expected).

Fields of papers citing papers by Benjamin Xiaoyi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Xiaoyi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Xiaoyi Li. The network helps show where Benjamin Xiaoyi Li may publish in the future.

Co-authorship network of co-authors of Benjamin Xiaoyi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Xiaoyi Li. A scholar is included among the top collaborators of Benjamin Xiaoyi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Xiaoyi Li. Benjamin Xiaoyi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Lü, Shun, Zhiwei Chen, Jiuwei Cui, et al.. (2023). Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial. JTO Clinical and Research Reports. 4(4). 100478–100478. 2 indexed citations
2.
Duan, Rong, Yixun Liu, Chuanliang Cui, et al.. (2022). Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4563–4563. 1 indexed citations
3.
An, Jusheng, Guiling Li, Jie Tang, et al.. (2022). Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.. Journal of Clinical Oncology. 40(16_suppl). 5526–5526. 2 indexed citations
4.
Adili, Reheman, et al.. (2021). Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice. Clinical and Applied Thrombosis/Hemostasis. 27. 2975200014–2975200014. 1 indexed citations
5.
Li, Hui, Peony Hiu Yan Poon, Chun Yeung, et al.. (2020). Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. Cancers. 12(10). 2935–2935. 5 indexed citations
6.
Jing, Zhi‐Cheng, Xinli Li, Lei Pan, et al.. (2016). Effect of intravenous l-carnitine in Chinese patients with chronic heart failure. European Heart Journal Supplements. 18(suppl A). A27–A36. 8 indexed citations
7.
Xu, Xiaohong, Naadiya Carrim, Miguel A. D. Neves, et al.. (2016). Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies. Thrombosis Journal. 14(S1). 29–29. 149 indexed citations
8.
Guo, Yugang, Jing Wu, Wei Chen, et al.. (2015). Balancing the Expression and Production of a Heterodimeric Protein: Recombinant Agkisacutacin as a Novel Antithrombotic Drug Candidate. Scientific Reports. 5(1). 11730–11730. 11 indexed citations
9.
Lei, Xi, Reheman Adili, Yan Hou, et al.. (2013). Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thrombosis and Haemostasis. 112(2). 279–289. 105 indexed citations
10.
Hou, Yan, Xi Lei, Benjamin Xiaoyi Li, et al.. (2013). The First In Vitro and In Vivo Assessment Of Anfibatide, a Novel Glycoprotein Ib Antagonist, In Mice and In a Phase I Human Clinical Trial. Blood. 122(21). 577–577. 11 indexed citations
11.
Sun, Yuanjue, Baorui Liu, Ping Liu, et al.. (2012). A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine (ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN).. Journal of Clinical Oncology. 30(15_suppl). 9017–9017. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louise J. Eltringham‐Smith Breakdown of academic impact, for papers by Kathrin Schwierczek Breakdown of academic impact, for papers by Daniëlle M. Coenen Breakdown of academic impact, for papers by Jens Posma Breakdown of academic impact, for papers by Surasak Wichaiyo Breakdown of academic impact, for papers by Péter Batár Breakdown of academic impact, for papers by Iván Parra‐Izquierdo Breakdown of academic impact, for papers by Wen Gao Breakdown of academic impact, for papers by Sascha Meyer dos Santos Breakdown of academic impact, for papers by Kristin N. Kornerup
Rankless by CCL
2026